expert views, Insiders

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they’re not changing medical practice — yet

Editor's note: I asked lung cancer expert Jack West — a thoracic oncologist at the Swedish Cancer Institute at Swedish Medical Center — to take a look at the new data from Bristol-Myers Squibb from Checkmate-227. He makes some excellent points about the way Bristol-Myers presented this data, with its broad definition of tumor mutation burden as a biomarker-defined endpoint. The detailed comments are worth studying closely. It's clear that Bristol-Myers has a significant way to go before they can convince practitioners to change the way they treat lung cancer. -- John Carroll, Editor

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 30,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->